You are here:
EU Project PerForM-REACT Strengthens Pandemic Preparedness Efforts
On March 11, 2024, the inauguration of the expanded safety laboratory in Augsburg marked a milestone within the EU-funded "PerForM-REACT" project, aimed at enhancing pandemic…
TherVacB, a novel therapeutic vaccine to combat chronic hepatitis B, entered the first clinical trial. The vaccine was designed and developed under the leadership of Helmholtz Munich. This phase 1a clinical trial is conducted at the Division of…
2023 has changed the way we treat obesity. A new class of drugs, mimicking a gut hormone called glucagon-like peptide-1 (GLP-1), is reshaping medicine and improving many people’s lives globally. GLP-1 drugs do not only induce significant weight loss,…
Redefining a Global Problem and an Urgent Need to Decipher the Disease’s Multiple Sub-Types
We urgently need more exchange about our findings from COPD research and clinical practice. But we need to broaden our perspective on the disease just as…
The AiChemist project has officially started in September 2023 Coordinated by Helmholtz Munich the project is an Innovative Doctoral Training Network funded with 3 million euros provided by the Marie Skłodowska-Curie Actions (MSCA-DN) within the EU…
Innovations and transfer are specifically promoted at Helmholtz Munich.
We use cookies to improve your experience on our Website. We need cookies to continually improve our services, enable certain features, and when we embed third-party services or content, such as the Vimeo video player. In such cases, information may also be transferred to third parties. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here:
